Peptide Therapy Guide

Clinics rarely prescribe a single peptide in isolation. These are the protocol patterns that recur across the source material, grouped by goal.

Peptide therapy sits in an awkward place: a handful of peptides are ordinary FDA-approved medicines, while most of the molecules discussed online are unapproved research compounds. This chapter separates the two and gives you the vocabulary used throughout this guide.

Provider quality varies enormously in this field, and the differences that matter — sourcing, testing, licensing, screening — are rarely visible on a clinic’s website. This chapter is a vetting checklist.

Most peptides ship as lyophilised powder and must be reconstituted before injection. The arithmetic and handling rules below are the same regardless of which peptide you are working with.

Price is driven less by the molecule and more by whether a peptide is FDA-approved (insurable) or research-grade (cash-pay). This chapter breaks down the cost structure and lists reported price points.

Timelines vary by peptide class: GLP-1 receptor agonists produce measurable changes within weeks, while reparative and longevity peptides are described in months. This chapter collects the timelines and the factors that reliably change outcomes.

Side effect profiles cluster more by route and dose than by molecule. Injection-site reactions, gastrointestinal effects and dose-dependent responses recur across nearly every peptide in this guide; the peptide-specific differences are listed at the end.

There is no official dose for most of the peptides in this guide — the numbers in circulation come from animal studies, practitioner surveys and vendor convention. This chapter explains how those numbers are derived, how titration works, and what the reported ranges are for every peptide covered here.

Regulatory status is not static. Between 2022 and 2026 the FDA moved several peptides between Category 1, Category 2 and removal from the bulk drug substance list. This chapter tracks the decisions that changed what clinics can legally provide.

FDA approval, 503A/503B compounding eligibility, DEA scheduling and state law are four separate questions, and a peptide can be legal on three and prohibited on the fourth. This chapter explains the framework, then lists where each peptide in this guide currently stands.